Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Executes Stock Sale Under 10b5-1 Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $14.6714, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• On January 2, 2025, Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 10,000 shares of common stock.
• The sale was executed under a 10b5-1 trading plan adopted on March 5, 2024, with an end date of May 30, 2025.
• The shares were sold at a weighted average price of $14.6714, with individual transaction prices ranging from $14.16 to $15.11.
• Following the transaction, Welgus directly owns 151,944 shares of Arcutis Biotherapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each respective price within the range set forth in the footnote, upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is part of a pre-planned trading strategy and doesn't necessarily reflect a change in the director's outlook on the company.

Future Outlook

The 10b5-1 trading plan will continue to be in effect until May 30, 2025, suggesting further transactions may occur.

Industry Context

Sales by insiders under 10b5-1 plans are common and allow insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales as less impactful than discretionary sales.

Comparison to Industry Standards

• Comparing Arcutis Biotherapeutics to companies like Dermavant Sciences or Cassiopea, which are also in the dermatology space, insider trading activity is a common occurrence.
• The use of 10b5-1 plans is a standard practice among executives and directors to manage their stock sales in a compliant manner.
• The size of this transaction (10,000 shares) is relatively small compared to the total outstanding shares of Arcutis Biotherapeutics and the trading volume, suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates